XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Balance Sheet Components - Additional Information (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Jul. 31, 2021
Schedule of Available-for-sale Securities [Line Items]            
Cash and cash equivalents $ 140,714,000   $ 140,714,000   $ 113,688,000  
Impairment loss 0 $ 0 0 $ 0    
API and bulk drug product price true-up 10,991,000   10,991,000   50,978,000  
Accrued inventory related cost 8,521,000   8,521,000   0  
Accrued litigation settlement 28,500,000   28,500,000   28,500,000  
Net unbilled co-development revenue 0   0   0  
Litigation settlement receivable 28,500,000   28,500,000   28,500,000  
Short-term investments 0   0   121,898,000  
Long-term investment 0   0      
Eluminex Agreements [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Aggregate consideration received for milestone and upfront payments 4,000,000   4,000,000   4,000,000 $ 8,000,000
AstraZeneca Agreements [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Inventory write-down     12,600,000      
Net unbilled co-development revenue 23,300,000   23,300,000   22,500,000  
Payment to related parties 11,500,000          
Astellas Agreement [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Payment to related parties 35,300,000          
Foreign subsidiaries [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Cash and cash equivalents $ 39,300,000   $ 39,300,000   $ 32,200,000